Targeting Mtb isocitrate lyase for the treatment of tuberculosis


J Reynisson1; R P Bhusal2; K Patel2; B X Kwai2; G Bashiri2; J Sperry2; I K Leung2
1 Keele University, UK;  2 University of Auckland, New Zealand


enzymes isocitrate lyase (ICL) isoforms 1 and 2 are essential for Mycobacterium tuberculosis survival
within macrophages during latent tuberculosis (TB).1 As such; ICLs
are attractive therapeutic targets for the treatment of tuberculosis. However,
there are few biophysical assays that are available for accurate kinetic and
inhibition studies of ICL in vitro. Here
we report the development of a combined NMR spectroscopy and thermal shift
assay to study ICL inhibitors for both screening and inhibition constant (IC50)
measurement. Operating this new assay in tandem with virtual high-throughput
screening has led to the discovery of several new ICL1 inhibitors.2
Furthermore, the crystal structure of the ICL2 isoform is reported, which has
been poorly understood until now. It is shown that ICL2 plays a pivotal role
regulating carbon flux between the TCA, glyoxylate and methylcitrate cycles at
high lipid concentrations, a mechanism essential for bacterial growth and
1. Bhusal, R. P. et al. Drug Discov. Today 2017,
22, 1008–1016.

2. Bhusal, R. P.
et al. Med. Chem. Commun. 2017, 8, 2155–2163.

3. Bhusal, R. P.
et al. Nature Commun. 2019, 10,

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021